Compare ProShares Ultra Gold ETF (UGL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Gold ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 178× ProShares Ultra Gold ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra Gold ETF for 23 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| UGL | VRTX | |
|---|---|---|
Market Cap | $716.59M | $127.55B |
Volume | 2,592,878 | 1,487,944 |
Sector | Leveraged / Inverse | Health |
52-Week High | $85.62 | $557.96 |
52-Week Low | $42.79 | $407.37 |
Typical Hold Time | 23 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UGL trades at $45.08, up 1.46% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Support is clustered around $44-$45, while resistance sits near $46. Recent news highlights gold's volatility amid shifting Fed rate expectations and Treasury yield pressures, impacting gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds like rising yields. Upside depends on sustained gold price recovery, but near-term risks from Fed policy and dollar strength suggest limited bullish catalysts. Investors should weigh the stock's sensitivity to commodity cycles against current bearish signals.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
